Respiratory Syncytial Virus
Diagnostics Market - Market Dynamics
High prevalence of respiratory
infections due to RSV is a major factor driving growth of the Respiratory
Syncytial Virus Diagnostics Market. According to a report by the Lancet,
2017, around 33•1 million episodes of RSV induced acute lower respiratory
infections that resulted in around 3•2 million hospitalizations and around
59,600 in-hospital deaths in children younger than 5 years of age, worldwide,
in 2015. Moreover, the report stated that the overall RSV- acute lower
respiratory infections- related mortality was around 118200 in 2015.
Furthermore, high prevalence of
several chronic conditions such as pneumonia and other respiratory tract
infections due to RSV is a major factor contributing to growth of the market
over the forecast period. For instance, according to a report by World Health
Organization (WHO), May 2018, chronic obstructive pulmonary disease (COPD) and
lower respiratory tract infection are amongst top five chronic diseases with
highest mortality rate, worldwide. The report stated that around 3 million each
deaths were registered due to COPD and lower respiratory tract infection in
2016, worldwide.
Respiratory Syncytial Virus (RSV)
is responsible for many chronic conditions such as pneumonia, bronchitis,
asthma, and respiratory disease. It primarily affects neonates, infants and
adults and is responsible for outpatient visits, hospitalization and death in
some cases. Therefore, diagnosis of RSV-
associated diseases is crucial to avoid further medical severity.
Symptoms of RSV presence include,
rhinorrhea, cough, wheeze, respiratory distress, and hypoxemia. Molecular
diagnostic is most widely used techniques for diagnosing RSV.
Respiratory Syncytial Virus
Diagnostics Market - Regional Insights
On the basis of Geography,
respiratory syncytial virus diagnostics market is segmented into North America,
Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is
expected to be dominant in the respiratory syncytial virus diagnostics market
over the forecast period.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2038
According to study published in
journal American Family Physician in 2017, around 2% to 3% of infants, younger
than 12 months are hospitalized with an RSV infection, annually, in the U.S. As
per same source, Around 57,500 hospitalizations and 2.1 million outpatient
visits are associated with RSV infections in children younger than five years,
annually, in the U.S. It can be concluded from epidemiological data that the
U.S. has high potential for respiratory syncytial virus diagnostics market.
Presence of key players and their products in North America would be another important
driver for the market growth.
Asia Pacific and Latin America
would witness highest CAGR in respiratory syncytial virus diagnostics market.
According to study published in the Lancet in September 2017, lower middle
income countries witnessed around 43,600 deaths due to RSV-ALRI whereas upper
middle income countries witnessed around 17900 deaths, in 2015.
Furthermore, children in this
region often do not receive adequate vaccination, which leads to frequent
infection incidences from variety of diseases including RSV. According to World
Health Organization (WHO) 2018, worldwide, around 86% of infants are vaccinated
against 26 diseases. However, around 19.5 million children remain unvaccinated
that leads to around 2-3 million deaths, annually, of which around 90% belong
to low and middle income countries.
WHO is running the pilot projects
of vaccination in countries of developing regions such Latin America, Africa,
and Asia Pacific to achieve100% detection of the RSV infections amongst
infants, neonates and children under five years of age.This is expected to
reduce the mortality rate and
hospitalization from RSV associated acute lower respiratory infections (ALRI).
It would also establish RSV diagnostic centers over the forecast period in
these regions.
Respiratory Syncytial Virus
Diagnostics Market - Competitive Landscape
Key players operating in the
respiratory syncytial virus diagnostics market include, F. Hoffmann La-Roche AG
, Becton, Dickinson and Company, Novartis AG, Abbott Laboratories, Ortho
Clinical Diagnostics, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc.,
BioMerieux, DiaSorin SPA, Millipore-sigma, Quidel Corporation, Alere Inc.,
Coris BioConcept, Fast-track Diagnostics, and Quest Diagnostics.
Moreover, the key players are
focused on new product launches to expand their market share. For instance.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/respiratory-syncytial-virus-diagnostics-market-2038
In 2016, BD (Becton, Dickinson
and Company) launched its wireless rapid diagnostic system named—Veritor Plus—
for detection of respiratory syncytial virus (RSV), influenza A and B, and
group A strep—with new traceability and secure patient-health record
documentation features and functionality.
In October 2017, Abbott
Laboratories completed acquisition of the Alere, Inc. which provides RSV
diagnostic system such as ALERE i RSV.
Key Development
In May 2019, QIAGEN N.V. received
510 (k) clearance from US Food and Drug administration (FDA) for its QIAstat-Dx
syndromic testing system
In 2016, BD (Becton, Dickinson
and Company) launched its next generation wireless rapid diagnostic system
Veritor Plus.
In 2017, Abbott Laboratories
completed acquisition of the Alere, Inc. which provides RSV diagnostic system
such as ALERE i RSV.
In 2016, Abbott Laboratories
received the US Food and Drug Administration (FDA) approval and CLIA waivers
for its Alere i RSV Rapid Molecular Test and Alere Reader Lateral Flow Assay
Analyzer respectively.
In September 2015, Roche
Diagnostics received CLIA from the US Food and Drug Administration (FDA) for
detection of flu A/B, RSV, and Strep A using the cobas Liat System. Post the
approval the system may be used in pharmacy clinics, hospitals, physician
offices, and other healthcare providing facilities.
In 2014, bioMérieux acquired
BioFire Diagnostics Inc., which is a privately held U.S.-based company
specialized in manufacturing molecular biology.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2038
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment